

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

**ANNOUNCEMENT
PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD
FOR THE SIX MONTHS ENDED 30 JUNE 2026**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 17 August 2026 (the “**Announcement**”) in relation to the preliminary financial data for the six months ended 30 June 2026 (the “**Reporting Period**”) of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

Unit: Ten Thousand Yuan
Currency: RMB

	The Reporting Period	Same period of last year	Increase/Decrease
Total revenue	3,626,635.60	3,679,659.84	-1.44%
Operating profit	83,443.04	92,649.65	-9.94%
Total profit	82,738.49	91,811.33	-9.88%
Net profit attributable to shareholders of the listed company	60,620.36	66,590.73	-8.97%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	59,887.41	64,286.16	-6.84%
Basic earnings per share (Yuan/share)	0.99	1.09	-9.17%
Weighted average return on net assets (%)	3.21%	3.70%	Decreased by 0.49 percentage point
	At the end of the Reporting Period	At the beginning of the Reporting Period	Increase/Decrease
Total assets	4,817,051.39	4,909,627.10	-1.89%
Equity attributable to shareholders of listed company	1,887,332.30	1,860,996.33	1.42%
Share capital (in 0'000 shares)	61,222.16	55,656.51	10.00%
Net assets per share attributable to shareholders of listed company (Yuan/share)	30.83	30.40	1.41%

Notes:

1. The above data is prepared based on the consolidated financial statements of Sinopharm Accord.
2. At the 2025 annual general meeting of Sinopharm Accord held on 21 May 2026, the "2025 Profit Distribution Proposal of Sinopharm Accord" was approved, pursuant to which a cash dividend of RMB6.16 per 10 shares (before tax) was distributed and 1 bonus share per 10 shares was issued to all shareholders based on a total share capital of 556,565,077 shares as at the end of 2025, resulting in an issuance of 55,656,507 bonus shares and an increase in total share capital of Sinopharm Accord to

612,221,584 shares. The equity distribution was completed for A shares on 24 June 2026 and for B shares on 26 June 2026. In accordance with the relevant requirements of the "Rules on Information Disclosure and Preparation by Companies Offering Securities to the Public No. 9 — Calculation and Disclosure of Return on Net Assets and Earnings Per Share", Sinopharm Accord has recalculated the earnings per share for the comparative period based on the total share capital after the bonus share issuance, and has also recalculated the net assets per share attributable to shareholders of the listed company. The basic earnings per share for the same period of last year and the net assets per share attributable to shareholders of the listed company at the end of last year were adjusted from RMB1.20 and RMB33.44 to RMB1.09 and RMB30.40, respectively.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

In the first half of 2026, Sinopharm Accord achieved a revenue of RMB36.266 billion, representing a year-on-year decrease of 1.44%; operating profit of RMB834 million, representing a year-on-year decrease of 9.94%; total profit of RMB827 million, representing a year-on-year decrease of 9.88%; and net profit attributable to shareholders of the listed company of RMB606 million, representing a year-on-year decrease of 8.97%. Accordingly, the basic earnings per share decreased by 9.17% year-on-year. Revenue and profit showed a narrowing decline compared to the first quarter, while the weighted average return on net assets decreased by 0.49 percentage point year-on-year.

In the first half of 2026, the distribution segment has achieved a revenue of RMB26.539 billion, representing a year-on-year decrease of 0.91%; and a net profit of RMB460 million, representing a year-on-year decrease of 4.56%. Despite the continuing impact of deepening industry policies and short-term pressure on the segment's operations, Sinopharm Accord demonstrated strong operational resilience by expanding growth, adjusting its structure, and implementing refined management, resulting in a continued narrowing of the decline in revenue and profit. The retail segment (i.e., Sinopharm Holding Guoda Drugstore Co., Ltd., **“Guoda Drugstore”**) has achieved a revenue of RMB10.227 billion, representing a year-on-year decrease of 2.40%, with the decline narrowing, and a net profit of RMB13 million, representing a year-on-year decrease of 19.74%. Affected by factors such as industry policy adjustments and intensified market competition, Guoda Drugstore's sales revenue declined slightly; coupled with changes in the sales structure, the sales proportion of high-margin products decreased, leading to a reduction in gross profit and consequently a decrease in profit.

In 2026, policies such as centralized procurement in the pharmaceutical industry continued to deepen, drug prices continued to decline, industry profit margins continued to narrow, and the terminal market structure accelerated its restructuring. Faced with profound industry changes and multiple uncertainties in the external environment, Sinopharm Accord has consistently adhered to its established strategy, proactively responding to challenges with high-quality development. Sinopharm Accord continues to refine and control operating costs, actively explore incremental market opportunities, optimize its product structure, strive to overcome development bottlenecks, and ensure stable operation.

Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the interim report of Sinopharm Accord may differ.

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
17 August 2026

As at the date of this announcement, the executive directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.